Founded in December 2017，We are a clinical-stage biopharmaceutical company committed to developing novel and highly differentiated, modality-independent therapeutic candidates to treat cancer and Nephropathy.

Headquarter&Translation Medicine Center
Wuxi

R&D Center
Shanghai

North China Operation Center
Shijiazhuang&Beijing

South China Operation Center
Guangzhou

Central China Operation Center
Wuhan

Strategy

            Joint R&D for potential BIC pipeline
          
            2017-12-28
          
            Building a leading edge in the clinical trial system
          
            Enhancing in-house R&D capabilities and Transforming to Global Innovation
          
            Integrate resources to strengthen commercialization capabilities

News

10 2024.04

BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3（GPC3）

03 2024.03

BioCity Announces Enrollment Completion of the IgA Nephropathy (IgAN) Cohort in the Randomized, Placebo-controlled Phase II Clinical Trial of the ETA Receptor Antagonist SC0062

20 2023.12

BioCity announces the first patient dosed with its anti-TIM-3 mAb BC3402 in Combination with IMFINZI for the Treatment of Advanced Hepatocellular Carcinoma in a Phase Ib/II Trial

15 2023.11

Riding the tide, realize the future: The BD paths for Chinese Biotech

The Interview of Dr. Kaan Certel （The CBO of BioCity)

Career

We have always been adhering to the mission of "Better Medicine for Better Life", and dedicate to developing "BIC/FIC" drugs with unmet needs.
We invite like-minded you to join us to create a healing tomorrow together.

Join Us